News releases - Merck.com
WEB5 days ago · September 11, 2024. Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males. September 07, 2024. Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase …
Merck wins first FDA approval for Keytruda as a treatment for ...
WEB4 days ago · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
WEBFeb 1, 2024 · Initiated More Than 20 Phase 3 Study Starts, Including the Progression of Eight Novel Assets Into Phase 3 in 2023. Augmented Pipeline Through Acquisitions of Prometheus and Imago, and Collaboration Agreements With Daiichi Sankyo and Kelun-Biotech in 2023. Full-Year 2024 Financial Outlook.
Merck (MRK) earnings Q2 2024 - CNBC
WEBJul 30, 2024 · Merck on Tuesday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations as it saw strong sales from its blockbuster cancer drug Keytruda as well as other...
Merck to Acquire EyeBio - Merck.com
WEBMay 29, 2024 · Merck to acquire EyeBio for a $1.3 billion upfront payment and up to $1.7 billion in future milestone payments for a potential value of $3 billion.
Merck Enters Two Strategic Collaborations to Strengthen AI …
WEBSep 20, 2023 · Merck, a leading science and technology company, today announced two new strategic drug discovery collaborations aimed at harnessing powerful artificial intelligence (AI)-driven design and discovery capabilities, further advancing the company’s research efforts.
News & Stories - Merck
WEBSep 12, 2024 · Check out the latest Merck news and stories! Learn more about the leading science and technology company here.
Merck Announces Fourth-Quarter and Full-Year 2023 Financial …
WEBFeb 1, 2024 · MRK. Fourth-Quarter and Full-Year Sales Reflect Sustained Growth Across Oncology and Vaccines. Fourth-Quarter Worldwide Sales Were $14.6 Billion, an Increase of 6% From Fourth Quarter 2022;...
Merck & Co., Inc. (MRK) Latest Stock News & Headlines
WEBGet the latest Merck & Co., Inc. (MRK) stock news and headlines to help you in your trading and investing decisions.
Merck raises 2024 profit forecast on surging sales of cancer drug ...
WEBApr 25, 2024 · Merck & Co on Thursday raised its annual profit and revenue forecasts on the back of double-digit growth for its blockbuster cancer drug Keytruda, the world's top selling prescription medicine.